Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Cardiac disorders – page 37

  • 481 clinical trials
  • 225 recruiting
  • 172 conditions
  • 28 countries

Conditions in this area

172 conditions with trials, the busiest first

Atrial fibrillation55Cardiac failure42Coronary artery disease37Acute myocardial infarction30Cardiac amyloidosis29Acute coronary syndrome21Cardiac arrest19Cardiac failure chronic17Cardiovascular disorder16Heart failure with reduced ejection fraction16Hypertrophic cardiomyopathy16Cardiac failure acute14Glycogen storage disease type II14Heart failure with preserved ejection fraction13Myocardial infarction13Cardiomyopathy11Myocardial ischaemia11Cardiogenic shock10Chronic coronary syndrome10Dilated cardiomyopathy9Myocarditis9Aortic valve stenosis7Chronic kidney disease6Trisomy 216+148

Clinical trials in Cardiac disorders

481 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

481 clinical trials

Coronary artery dissection

Not recruiting

Study on the Effects of Metoprolol, Prasugrel, and Carbasalate Calcium in Patients with Spontaneous Coronary Artery Dissection

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Atenolol
  • Sponsor:Spanish Society Of Cardiology

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Bayer AG

Pneumonia+2

Not recruiting

Study on Aspirin and Pantoprazole for Reducing Heart Attack Risk in Hospitalized Pneumonia Patients

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Amsterdam UMC Stichting

Heart failure with preserved ejection fraction

Not recruiting

Study on the Effects of Colchicine for Patients with Heart Failure with Preserved Ejection Fraction (HFpEF)

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Gentofte Hospital

Coronary artery disease

Not recruiting

Study on Reduced Antiplatelet Therapy with Acetylsalicylic Acid and Clopidogrel for Patients with Coronary Artery Disease After Stent Implantation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Ivascular S.L.

Hypertrophic cardiomyopathy

Not recruiting

Long-term Safety Study of Mavacamten for Adults with Hypertrophic Cardiomyopathy from Previous Trials

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Mitral valve incompetence+2

Not recruiting

Study on the Effects of Sacubitril and Valsartan in Patients with Heart Failure and Mitral Valve Regurgitation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sacubitril
  • Sponsor:Ziekenhuis Oost Limburg

Glycogen storage disease type II

Not recruiting

Study on the Safety and Efficacy of Cipaglucosidase Alfa and Miglustat for Children with Late-onset Pompe Disease

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Cipaglucosidase Alfa
  • Sponsor:Amicus Therapeutics Inc.

Acute myocardial infarction

Not recruiting

Study to Test BI 765845 for Patients with Heart Attack

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bi 765845
  • Sponsor:Boehringer Ingelheim Espana S.A.

Hypertrophic cardiomyopathy

Not recruiting

Study Comparing Aficamten and Metoprolol for Adults with Symptomatic Hypertrophic Cardiomyopathy

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Aficamten
  • Sponsor:Cytokinetics Inc.

Cardiomyopathy

Not recruiting

Study on the Safety and Effects of OMT-28 for Patients with Primary Mitochondrial Disease and Muscle or Heart Problems

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:2-{[(8Z)-13-[(Methylcarbamoyl)Formamido]-Tridec-8-En-1-Yl]Oxy}Acetic Acid
  • Sponsor:OMEICOS Therapeutics GmbH

Acute myocardial infarction+5

Not recruiting

Study on the Effects of Zalunfiban for Patients with ST-Elevation Myocardial Infarction (Heart Attack)

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zalunfiban
  • Sponsor:Celecor Therapeutics Inc.

Substances studied in this area

The therapies tested most often in Cardiac disorders trials.

Acetylsalicylic Acid44 clinical trialsClopidogrel30 clinical trialsTicagrelor27 clinical trialsSodium Chloride25 clinical trialsDapagliflozin22 clinical trialsApixaban21 clinical trialsEmpagliflozin20 clinical trialsRivaroxaban19 clinical trialsPrasugrel18 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.